1. 206120735 一种血液制品制备中的低pH孵放罐
CN
26.04.2017
A61J 1/05 Loading...
A61J 1/05
Loading...
201620652022.0
江西博雅生物制药股份有限公司
张丽铃
A61J 1/05
Loading...
本实用新型涉及一种血液制品制备中的低pH孵放罐，包括罐体，在罐体上设有端盖，罐体内设有内胆，内胆与罐体之间形成空腔，罐体上设有与空腔连通的蒸汽入口和蒸汽出口，通过蒸汽入口连接外界的高温蒸汽可以对内胆进行高温消毒处理，高温蒸汽可以通过蒸汽出口随时排出，内胆消毒方便，而且在内胆的内壁上设有多个相互交错设置的隔板，增大了内胆中血液制品的附着面积，防止沉淀，罐体的底部设有与内胆连通的输液管，输液管的端部设有密封套，输液管可以连接抗凝剂，随时给孵放罐添加抗凝剂的剂量，防止孵放罐中的血液制品凝固，改变了传统人工添加抗凝剂的方式，使用方便。
2. 104231075 一种乙型肝炎人免疫球蛋白的制备工艺
CN
22.03.2017
C07K 16/08 Loading...
C07K 16/08
Loading...
201410442079.3
江西博雅生物制药股份有限公司
徐建新
C07K 16/08
Loading...
本发明公开了一种乙型肝炎人免疫球蛋白的制备工艺，其特征是制备工艺如下：采用高于标准的血浆，通过低温乙醇法及压滤法分离得到组分Ⅱ+Ⅲ沉淀，经溶解、压滤得到精制组分Ⅱ+Ⅲ沉淀，再经溶解、调整反应参数、压滤、深层过滤、超滤、透析步骤，调整蛋白液参数，使用DEAE Sepharose Fast Flow弱阴离子交换凝胶进行上柱层析纯化，经超滤、调整pH为4.05～4.15，加入麦芽糖作为保护剂；经低pH孵放病毒灭活及DV20滤芯除病毒，二次超滤，控制麦芽糖残留量不高于2g/L，再加入甘氨酸作为保护剂等，制备出纯度在99.0%以上、IgG单体及二聚体总含量在98.0%以上、效价不低于100IU/ml的特异性乙型肝炎人免疫球蛋白。本发明收得率较传统低温乙醇法可提高7.5~10%。
3. 104231072 一种从冷沉淀提取凝血因子Ⅷ的废料中提取人纤维蛋白原的制备工艺
CN
22.03.2017
C07K 14/75 Loading...
C07K 14/75
Loading...
201410524351.2
江西博雅生物制药股份有限公司
杨笃才
C07K 14/75
Loading...
本发明公开了一种从冷沉淀提取凝血因子Ⅷ的废料中提取人纤维蛋白原的制备工艺，其特征在于包括：冷沉淀溶解、2%氢氧化铝凝胶吸附、调节离子强度、串联过滤、S/D病毒灭活、离子交换层析、EDTA除Ca2+、甘氨酸沉淀、第一次低温乙醇沉淀、AT‑Ⅲ抑制凝血酶、第二次低温乙醇沉淀、纳米膜过滤以及干热灭活。本发明为了确保安全性，除了S/D及干热灭活外，新增纳米膜过滤除病毒；新增AT‑Ⅲ灭活凝血酶及EDTA除Ca2+工艺，有效阻止在生产过程中纤维蛋白原激活成纤维蛋白；用甘氨酸沉淀去除制品中的纤维蛋白单体和多聚体，以获得高纯度的人纤维蛋白原；所得制剂产品安全可靠，复溶时间短，满足临床上救急之需，同时间接节约稀缺血浆资源具有重要意义。
4. 205769418 一种血液制品移动洁净小车
CN
07.12.2016
B62B 3/00 Loading...
B62B 3/00
Loading...
202016000652568
江西博雅生物制药股份有限公司
黄燚
B62B 3/00
Loading...
本实用新型涉及一种血液制品移动洁净小车,包括箱体，在箱体内设有多层隔网，隔网将箱体分隔为多个安置腔，箱体上设有多个与其安置腔连通的通孔，箱体上设有橡胶手套，橡胶手套与通孔密封连接，人手从箱体外面通过橡胶手套深入到安置腔内对血液制品任意摆放，箱体的顶部设有消毒液箱，消毒液箱内注入消毒液，消毒液箱的底部设有多个喷头，箱体底部的底板与箱体内最下层的隔网围成消毒液收集腔，在消毒液收集腔内设有收集托盘，收集托盘内设有微型吸泵，微型吸泵通过软管与箱体顶部的消毒液箱连接，消毒液箱的喷头喷出消毒液对安置腔内的血液制品包装袋进行消毒处理，被使用的消毒液从隔网漏入到收集托盘内，通过微型吸泵和软管可以导入到消毒液箱内循环使用。
5. 205738329 一种间歇式自动装盒机
CN
30.11.2016
B65B 43/52 Loading...
B65B 43/52
Loading...
202016000652024
江西博雅生物制药股份有限公司
梁小明
B65B 43/52
Loading...
本实用新型涉及一种间歇式自动装盒机，包括支架，在支架上设有传送平台，在传送平台上设有传送带，在传送带上设有多个隔板，相邻隔板之间形成安置腔，在安置腔内放置包装盒，传送带的正上方的一侧设有药品投放机构，传送带上方的另一侧设有贴标机构，传送带上相邻隔板之间形成的安置腔的底部设有重量传感器，传送带靠近贴标机构的端部设有贴标扫描仪，重量传感器可以感应包装盒的重量，包装盒在空置时，重量传感器即可向控制器传送对应包装盒的漏装信息，同理，贴标扫描仪也可以扫描被贴标签的包装盒，在出现标签漏贴时，控制器即可将对应包装盒的漏贴信息反馈给工作人员，使用方便。
6. 205732194 一种血浆袋清洗机
CN
30.11.2016
B08B 9/093 Loading...
B08B 9/093
Loading...
202016000652569
江西博雅生物制药股份有限公司
饶振
B08B 9/093
Loading...
本实用新型涉及一种血浆袋清洗机,包括清洗箱，在清洗箱的顶部设有清洗总管，在清洗总管上设有多个清洗喷头，清洗箱的底部设有传送带，传送带内侧设有传动轮，传送带上设有若干漏液孔，血浆袋可以放置在传送带上，通过清洗喷头喷出清洗液进行清洗，清洗箱的底部设有接液盘，接液盘通过连接管与清洗总管连接，接液盘内设有与连接管连接的液泵，由于传送带上设有若干漏液孔，传送带上被利用的清洗液从漏液孔落入到接液盘内，被液泵进一步导入到清洗总管中进行循环再利用。
7. 205700230 一种血液制品沉淀破冰机
CN
23.11.2016
B01F 7/04 Loading...
B01F 7/04
Loading...
201620651967.0
江西博雅生物制药股份有限公司
杨笃才
B01F 7/04
Loading...
本实用新型涉及一种血液制品沉淀破冰机,包括支架，在支架上设有箱体，箱体的顶部设有进料斗，箱体内设有固定套，固定套上设有进料口和出料口，固定套内设有转动辊轴，转动辊轴连接驱动电机，在转动辊轴的周面上设有多个搅拌桨叶，通过转动辊轴上的搅拌桨叶在固定套内转动从而达到血液制品沉淀破冰的目的，固定套远离驱动电机的端部设有活动密封板，活动密封板连接伸缩气缸，伸缩气缸带动活动密封板在固定套内轴向滑动，通过活动密封板来压缩固定套内的血液制品，使得固定套内的血液制品与搅拌桨叶充分接触，提高了破碎效率，而且支架上设有与固定套的出料口对应的通孔，在支架的下方连接有挂钩，挂钩上挂靠收料桶，加工后的血液制品收集方便。
8. 205708131 一种血液制品冷链保藏箱
CN
23.11.2016
B65D 81/38 Loading...
B65D 81/38
Loading...
201620651968.5
江西博雅生物制药股份有限公司
黄璠
B65D 81/38
Loading...
本实用新型涉及一种血液制品冷链保藏箱，包括箱体，在箱体上设有箱盖，箱体包括内胆和外壳，内胆与外壳之间形成空腔，在外壳上设有与空腔连通的单向注液阀，通过单向注液阀可以向空腔内注入冷却液，从而降低箱体的内部温度，为了提高箱体的强度，内胆与外壳之间设有多个加强支撑板，在加强支撑板上设有均设有通孔，空腔中的冷却液仍可以通过通孔进行流通，内胆的底部设有多个相互间隔交错的隔板，隔板之间围成安置腔，血液制品可以放置在安置腔内，外壳上连接有覆盖在单向注液阀表面的盖板，盖板的一端通过活动销轴与外壳连接，活动销轴上套设扭簧，盖板可以自由转动，从而有效防止灰尘落入到单向注液阀内，保证了冷链保藏箱的使用寿命。
9. 105622746 一种从冷沉淀提取凝血因子Ⅷ的废料中提取人血管性血友病因子的制备工艺
CN
01.06.2016
C07K 14/745 Loading...
C07K 14/745
Loading...
201610077346.0
江西博雅生物制药股份有限公司
杨笃才
C07K 14/745
Loading...
本发明公开了一种从冷沉淀提取凝血因子Ⅷ的废料中提取血管性血友病因子的制备工艺，用一步Q-Sepharose阴离子交换层析及一步亲和层析纯化得到纯度较高的vWF：收集冷沉淀提取凝血因子Ⅷ的废料即在冷沉淀提取凝血因子Ⅷ的制备中经层析柱流出来的液体作为原料；通过Q-Sepharose离子交换柱层析后，收集洗脱液，再经明胶亲和层析，去除残余的纤维结合蛋白及杂质，得到血管性血友病因子。本发明获得高纯度的血管性血友病因子，质量可靠，可满足临床上血管性血友病人急需的治疗用药需求。同时对于冷沉淀的综合利用，间接节约稀缺血浆资源具有十分重要的意义。
10. 105622747 一种vWF活性保护液
CN
01.06.2016
C07K 14/755 Loading...
C07K 14/755
Loading...
201610077438.9
江西博雅生物制药股份有限公司
杨笃才
C07K 14/755
Loading...
本发明公开了一种vWF活性保护液，用于从冷沉淀提取凝血因子Ⅷ的废料中提取血管性血友病因子的制备中，在血管性血友病因子的制备工艺中，对层析缓冲液加入甘氨酸，层析后冻干前的蛋白液中加入赖氨酸、甘氨酸和白蛋白，保护vWF活性。本发明层析缓冲液中加入甘氨酸可以在层析分离纯化过程中，减少vWF的活性损失。在蛋白透析液中加入白蛋白、赖氨酸、甘氨酸作为冻干保护剂，可稳定vWF分子。白蛋白是优良蛋白稳定剂，同时可以有效蛋白质表面的吸附。赖氨酸、甘氨酸为小分子氨基酸，可以保护蛋白质结构，能升高成品的塌陷温度，阻止冻干过程中因塌陷导致的蛋白质损伤。保持生物学活性。
11. 105541997 一种高纯度和高活性血管性血友病因子的制备工艺
CN
04.05.2016
C07K 14/745 Loading...
C07K 14/745
Loading...
201610077518.4
江西博雅生物制药股份有限公司
杨笃才
C07K 14/745
Loading...
本发明公开了一种高纯度和高活性血管性血友病因子的制备工艺，收集冷沉淀提取凝血因子Ⅷ的废料即在冷沉淀提取凝血因子Ⅷ的制备中经层析柱流出来的液体作为原料；在血管性血友病因子的制备工艺中，对经层析后的蛋白液在层析缓冲液中加入甘氨酸保护vWF活性；优选层析后冻干前的蛋白液中加入赖氨酸、甘氨酸和白蛋白作为冻干保护剂，保护vWF活性；本发明获得高纯度的血管性血友病因子，质量可靠，可满足临床上血管性血友病人急需的治疗用药需求。同时对于冷沉淀的综合利用，间接节约稀缺血浆资源具有十分重要的意义。
12. 101972479 Preparation process of intravenous injection human immunoglobulin
CN
16.02.2011
A61K 39/395 Loading...
A61K 39/395
Loading...
201010534828.7
Jiangxi Boya Biological Pharmaceutical Co., Ltd.
Xu Jianxin
A61K 39/395
Loading...
The invention relates to a preparation process of intravenous injection human immunoglobulin, belonging to the field of pharmaceuticals. On a basis of a traditional preparation process of intravenous injection human immunoglobulin with the low protein concentration of 5 percent, a filter pressing method is adopted instead of a centrifuging method in an extraction process. During hyperfiltration, the protein concentration is adjusted to 3-6 percent, a pH value is adjusted to 6.4-6.6 with 0.5 mol/L of NaOH; then, 1 mol/L phosphoric acid-NaOH buffer solution is added to adjust the electrical conductivity which is measured to be 0.175-0.205 s/m at a temperature T of 19 DEG C; and a chromatography method is adopted to carrying out column chromatography and purification by using upper ion exchange columns after the electrical conductivity is adjusted. The protein impurities can be effectively removed, the protein purify and the product yield are improved; maltose or glycin is used as a protector, which benefits the improvement of the stability of the intravenous injection human immunoglobulin; and the glycin is used as the protector, which satisfies the clinical use of diabetics. According to the invention, the intravenous injection human immunoglobulin with the protein concentration of 5-11 percent can be obtained.
13. 101974070 Preparation process of human prothrombin compound
CN
16.02.2011
C07K 1/36 Loading...
C07K 1/36
Loading...
201010534827.2
Jiangxi Boya Biological Pharmaceutical Co., Ltd.
Liao Xinxi
C07K 1/36
Loading...
The invention relates to a preparation process of a human prothrombin compound, belonging to the field of biological pharmacy. The preparation process comprises the following steps of: absorbing blood plasma, washing, eluting and clarifying by filtration; inactivating viruses by using the S/D (Solvent/Detergent) method; purifying by absorption; subpackaging; freeze-drying; and inactivating viruses by the dry heat method. The human prothrombin compound is directly absorbed from blood plasma by using gel, only the gel chromatography technology is used in the entire extraction process, so that the production steps are simplified, the pollution of various factors on the production process of the product is reduced, meanwhile, the yield of the product is increased by 25-30%. In addition, the S/D method is used for removing lipid-enveloped viruses and the dry heat method is used for removing non lipid-enveloped viruses in the production process, and the safety of clinic medication is obviously increased through the two virus inactivation steps.
14. 101967188 Process for preparing human antihemophilic factor VIII
CN
09.02.2011
C07K 14/755 Loading...
C07K 14/755
Loading...
201010534849.9
Jiangxi Boya Biopharmaceutical Co., Ltd.
Liang Xiaoming
C07K 14/755
Loading...
The invention relates to a process for preparing a human antihemophilic factor VIII, which belongs to the field of biological pharmacy. The process comprises the following steps of: melting a cryoprecipitate at room temperature for 1 to 2 hours and performing processing to obtain square blocks with side length of 1.8 to 2.2 cm; dissolving the cryoprecipitate; performing adsorption by using alumina gel; performing acid precipitation; performing S/D inactivation; filtering; performing DEAEsepHaroseFF chromatographic column equilibrium; performing DEAEsepHaroseFF chromatographic column regeneration, treatment and storage; chromatographing; washing; eluting; performing ultrafiltration and preparing liquid; split charging; freeze-drying; and performing inactivation by a dry heat processing method. An ion-exchange column chromatographic technique is adopted in the process and alumina gel adsorption and acid precipitation are adopted in the production process to remove impurities, so the specific activity of products is improved obviously, the product quality is improved obviously, and the yield of the products is increased by 30 to 35 percent. In addition, in the production process, fat enveloped viruses are removed by an S/D method and non-fat enveloped viruses are removed by a dry heat processing method at the temperature of 99.5+/-0.5 DEG C, so the safety of clinical medication is improved obviously through the two-time inactivation step.
15. 101229367 Process of preparing human fibrinogen preparation
CN
30.07.2008
A61K 38/36 Loading...
A61K 38/36
Loading...
200810046747.5
Jiangxi Boya Biopharmaceutical Co., Ltd.
Liang Xiaoming
A61K 38/36
Loading...
The invention relates to a method for preparing a human fibrinogen preparation, which is characterized in that the preparation method includes the following steps: (1) pulping; (2) sedimentation of a component I; (3) sedimentation of a component II; (4) sedimentation of a component III; (5) preparation of an original solution. The method for preparing the human fibrinogen preparation has the advantages that: the human fibrinogen produced by the technology has stable quality and the viral safety of the human fibrinogen is enhanced; dry hot virus inactivation technology in a temperature preservation condition of 99.5+/-0.5 DEG C for 30min is added on the basis of the original S/D virus inactivation technology so as to inactivate non-lipid-enveloped virus.

